Active, Not Recruiting

Trial ID CV185-664 | NCT03508258

Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)

Sorry, this study is no longer accepting new participants, but is still ongoing.

You may click the “Check Your Eligibility” button and answer a few questions about your health to find out if you might be a match to another study.

Check Your Eligibility

About This Trial
Key Eligibility Criteria

Summary

18+

Age Range
Active, Not Recruiting

Overview

Study of patients with nonvalvular atrial fibrillation (NVAF) who are newly prescribed NOACs (Novel Oral Anticoagulants) in routine clinical practice in England

Key Eligibility Criteria

Inclusion Criteria: - Diagnosis of atrial fibrillation at or prior to index (the initiation of treatment) - Incident prescription of an oral anticoagulant (index date) - Patients with at least one year of computerized data prior to index date Exclusion Criteria: - Patients identified with a diagnosis of mechanical heart valve replacement or mitral stenosis identified at any point in the pre-index period in either CPRD by Read codes or in HES as ICD-10/OPCS codes - Patients with indication of venous thromboembolism (pulmonary embolism or deep vein thrombosis) identified in in either CPRD by Read codes or HES by ICD-10/OPCS codes within 3 months prior to index Other protocol defined inclusion/exclusion criteria could apply

Treatment Options

Study Arms

ASSIGNED INTERVENTION

Study Arms

Participants with NVAF starting Apixaban

ASSIGNED INTERVENTION

Other: Non-interventional

Study Arms

Participants with NVAF starting Warfarin

ASSIGNED INTERVENTION

Other: Non-Interventional